#437 1982 · Bangladesh National Drug Policy (Zafrullah Chowdhury's Expert Committee, under Ershad's martial-law government) · Public health / pharmaceutical regulation
Bangladesh's health reformers used five weeks of unaccountable martial law to pass the drug reform an elected parliament would have let industry stall for years
问题
Bangladesh's drug market was flooded with roughly 5,000 registered products, many duplicative, unnecessary or unsafe, sold mostly by multinational firms, while the handful of medicines the country's actual disease burden needed were often out of stock or priced out of reach — and any ordinary attempt to fix this by law would face years of the same lobbying that had stalled essential-drug reform elsewhere.
背景
Post-independence Bangladesh's pharmaceutical market was built almost entirely on imported and multinational-manufactured products: vitamin tonics, cough syrups, and combination drugs of little medical value sat on pharmacy shelves — including an anabolic steroid, Orabolin, marketed as an appetite stimulant for malnourished children — while many of the roughly 150 medicines that actually treated the country's common diseases were scarce or unaffordable. WHO had published a model list of essential medicines in 1977, but adopting it meant deregistering thousands of products multinational companies profited from, and in most developing countries with a functioning legislature, that fight was fought — and usually lost — one hearing, one lobbyist, and one election cycle at a time.
On 24 March 1982, Lieutenant General Hussain Muhammad Ershad seized power in a coup, suspending Bangladesh's constitution and dissolving parliament — for the moment, there was no legislature left for a drug company to lobby. On 27 April 1982, barely five weeks later, the new government convened an eight-member expert committee and gave it a narrow, technical mandate: review every one of the country's roughly 5,000 registered drug products against WHO's essential-medicines criteria. Physician and health activist Zafrullah Chowdhury, already known for founding the rural health cooperative Gonoshasthaya Kendra, sat on the committee.
换别人会怎么做
Cap prices or negotiate volume discounts with the multinational suppliers directly — the standard lever against a market a few large firms dominate. It fails here because Bangladesh had no leverage over firms that could simply exit or under-supply a market they didn't need, and any legislative price-control bill would sit in front of the same lobbyists, editors, and foreign diplomats for years, the way essential-medicines reform had stalled in country after country that tried it through an ordinary legislature.
他们看到了什么
Chowdhury and the committee saw that the fight worth winning wasn't over price at all, but over registration — a category where the state, not the market, already held unquestioned authority to decide what could legally be sold — and that the five-week window after a coup, with parliament dissolved and no legislature left to lobby, was the one moment a technical committee's recommendation could become binding law before multinational firms or foreign governments had any normal channel to organize resistance against it.
那一手
The committee didn't route its findings through ministerial consultation, industry comment periods, or a bill that lobbyists could amend in committee — the channels every earlier essential-drugs push had died in. It delivered fast enough for Ershad to declare the National Drug Policy on 1 June 1982 and formalize it nine days later as the Drugs (Control) Ordinance No. VIII, a law enacted by martial-law decree rather than passed by any body drug companies had ever needed to lobby. The ordinance banned roughly 1,700 non-essential or harmful products outright, including Orabolin, and organized the market around a core list of 150 essential drugs plus 100 more reviewed every six months.
为什么管用
An elected legislature gives an opposing industry months of hearings, drafting sessions and relationship-building in which to dilute or kill a bill; a martial-law ordinance has none of those stages to exploit. By the time the US ambassador and the Reagan administration objected, the policy was not a proposal to be lobbied against but a signed law already praised by outside health bodies and already popular with a domestic public that saw it as standing up to foreign drug companies — which made reversing it cost Ershad's fragile new government more legitimacy, at home and abroad, than absorbing Washington's displeasure did. The country's political weakness relative to the US became irrelevant once the fight moved to a channel foreign pressure could not reach fast enough to matter.
值了多少
The US ambassador told Ershad the same morning the policy broke that it was 'not acceptable to Washington'; President Reagan personally pressed him to revise it, and Chowdhury later recounted the pressure reaching Ershad from Vice President George H.W. Bush during a Washington visit. But American scientists who reviewed the policy on its technical merits backed it, congratulatory letters arrived from health bodies and NGOs worldwide, and by the time Washington objected the policy was already signed law and already popular at home — reversing it would have cost Ershad's five-week-old government more legitimacy than defying an ally did, so it stood. Local production of essential drugs rose from about 30% to roughly 80% of the domestic market, prices stayed low for decades even as the taka devalued from 18 to 40 to the dollar, and Bangladesh's pharmaceutical sector grew from near-total import dependence into a net exporter of medicine.
什么时候会失灵
It needs a decision-maker who genuinely holds concentrated, unchallengeable authority for a limited window — an elected government mid-term, or one already answerable to the industry through cabinet ties or campaign finance, offers no such opening. It also needs the substance to be strong and popular enough to earn fast third-party legitimacy (WHO's framework, scientific endorsement, domestic public support); a weak or self-serving policy rushed through the same way invites reversal the moment the narrow window closes. And it works only once per window — an incumbent industry that has been burned this way will spend the next crisis making sure it has a seat on the committee before the ordinance is drafted.
后来呢
Health-policy scholarship (Reich, 1994) still treats 1982 as one of the rare instances of a poor country adopting pharmaceutical regulation squarely against multinational-industry and US-government pressure and having it hold. Chowdhury shared the 1992 Right Livelihood Award and won the 1985 Ramon Magsaysay Award substantially for this work, and Bangladesh's pharmaceutical industry — negligible in 1982 — now exports medicines to more than 150 countries.
资料来源
- [1]Bangladesh pharmaceutical policy and politicsHealth Policy and Planning (Oxford University Press), via PubMed, 1994pubmed.ncbi.nlm.nih.gov
- [2]Historicising state-NGO relations in global drug access campaigns: the case of the Bangladesh drug policy of 1982University of Manchester, Centre for the History of Medicine, 2025dhm.manchester.ac.uk
- [3]Dr Zafrullah Chowdhury: The revolutionary who transformed healthcareDown To Earth, 2023downtoearth.org.in